105
Views
8
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Hyaluronan with dextran added to therapeutic lung surfactants improves effectiveness in vitro and in vivo

, &
Pages 191-200 | Received 21 Dec 2012, Accepted 28 Mar 2013, Published online: 03 May 2013

REFERENCES

  • Matthay M, Zemans R: The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147–163.
  • Johnson E, Matthay M: Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 2010;23:243–252.
  • Zuo Y, Veldhuizen R, Neumann A, Petersen N, Possmayer F: Current perspectives in pulmonary surfactant–inhibition, enhancement and evaluation. Biochim Biophys Acta. 2008;1778:1947–1977.
  • Notter R, Finkelstein J, Holm B: Lung Injury: Mechanisms, Pathophysiology, and Therapy. NY: Taylor and Francis; 2005.
  • Walsh B, Brooks T, Grenier B: Oxygen therapy in the neonatal care environment. Respir Care. 2009;54:1193–1202.
  • Baudouin S: Exogenous surfactant replacement in ARDS–one day, someday, or never. N Engl J Med. 2004;351:853–855.
  • Clements J, Avery M: Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med. 1998;157:S59–S66.
  • Matthay M, Zimmerman G, Esmon C, Bhattacharya J, Coller B, Doershuk C, Floros J, Gimbrone M, Hoffman E, Hubmayr R, Leppert M, Matalon S, Munford R, Parsons P, Slutsky A, Tracey K, Ward P, Gail D, Harabin A: Future research directions in acute lung injury. Am J Respir Crit Care Med. 2003;167:1027–1035.
  • Seeger W, Gunther A, Walmrath H, Gimminger F, Lasch H: Alveolar surfactant and ARDS: Pathogenic role and therapeutic prospects. Clinical Investigation. 1993;71:177–190.
  • Hallman M, Merritt T, Akino T, Bry K: Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am Rev Respir Dis. 1991;144:1376–1384.
  • Lu K, Goerke J, Clements J, Taeusch H: Hyaluronan decreases surfactant inactivation in vitro. Pediatr Res. 2005;57:237–241.
  • Taeusch H, Lu K, Goerke J, Clements J: Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med. 1999;159:1391–1395.
  • Calkovska A, Mokra D, Drgova A, Zila I, Javorka K: Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration pneumonia. Eur J Pediatr. 2008;167:851–857.
  • Lu K, Taeusch H, Robertson B, Goerke J, Clements J: Polymer-surfactant treatment of meconium-induced acute lung injury. Am J Respir Crit Care Med. 2000;162:623–628.
  • Lu K, Taeusch H, Robertson B, Goerke J, Clements J: Polyethylene glycol/surfactant mixtures improve lung function after HCl and endotoxin lung injuries. Am J Respir Crit Care Med. 2001;164:1531–1536.
  • Lu K, Goerke J, Clements J, Taeusch H: Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium lung injury. Pediatr Res. 2005;58:206–210.
  • Lu K, Robertson B, Taeusch H: Dextran or polyethylene glycol added to Curosurf for treatment of meconium lung injury in rats. Biol Neonate. 2005;88:46–53.
  • Lu J, Cheung W, Yu L, Policova Z, Li D, Hair M, Neumann A: The effect of dextran to restore the activity of pulmonary surfactant inhibited by albumin. Respir Physiol Neurobiol. 2002;130:169–179.
  • Stichtenoth G, Jung P, Walter G, Johansson J, Robertson B, Curstedt T, Herting E: Polymyxin B/pulmonary surfactant mixtures have increased resistance to inactivation by meconium and reduce growth of gram-negative bacteria in vitro. Pediatr Res. 2006;59:407–411.
  • Zuo Y, Alolabi H, Shafiei A, Kang N, Policova Z, Cox P, Acosta E, Hair M, Neumann W: Chitosan enhances the in vitro surface activity of dilute lung surfactant preparations and resists albumin induced inactivation. Pediatr Res. 2006;60:125–130.
  • López-Rodríguez E, Ospina O, Echaide M, Taeusch H, Pérez-Gil J: Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer. Biophys J. 2012;103:1451–1459.
  • Lu K, Pérez-Gil J, Echaide M, Taeusch H: Pulmonary surfactant proteins and polymer combinations reduce surfactant inhibition by serum. Biochim Biophys Acta. 2011;1808:2366–2373.
  • Putz G, Goerke J, Taeusch W, Clements J: Comparison of captive and modified pulsating bubble surfactometers. J Appl Physiol. 1994;76:1425–1431.
  • Lu K, Taeusch H: Combined effects of polymers and KL(4) peptide on surface activity of pulmonary surfactant lipids. Biochim Biophys Acta. 2010;1798:1129–1134.
  • Iwanicki J, Lu K, Taeusch H: Reduction of phospholipase A2 inhibition of pulmonary surfactant with hyaluronan. Exp Lung Res. 2010;36:167–174.
  • Braun A, Stenger P, Warriner H, Zasadzinski J, Lu K, Taeusch H: A freeze-fracture TEM and small angle X-ray diffraction study of the effects of albumin, serum, and polymers on clinical lung surfactant microstructure. Biophys J. 2007;93:1–17.
  • Zasadzinski J, Alig T, Alonso C, de la Serna J, Perez-Gil J, Taeusch H: Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: Theory. Biophys J. 2005;89:1621–1629.
  • Zasadzinski A, Taeusch H: Polymer depletion forces and surfactant adsorption. Polymer Preprints. 2005;46:134–138.
  • Pasquali-Ronchetti I, Quaglino D, Mori G, Bacchelli B, Ghosh P: Hyaluronan-phospholipid interactions. J Struct Biol. 1997;120:1–10.
  • Scott J, Cummings C, Brass A, Chen Y: Secondary and tertiary structures of hyaluronan in aqueous solution, investigated by rotary shadowing-electron microscopy and computer simulation. Biochem J. 1991;274:699–705.
  • Collins S, Black K, Chan-Li Y, Ahn Y, Cole P, Powell J, Horton M: Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor. Am J Respir Cell Mol Biol. 2011;45:675–683.
  • Mascarenhas M, Day R, Ochoa C, Choi W, Yu L, Ouyang B, Garg H, Hales C, Quinn D: Low molecular weight hyaluronan from stretched lung enhances interleukin-8 expression. Am J Respir Cell Mol Biol. 2004;30:51–60.
  • McKee C, Penno M, Cowman M, Burdick M, Strieter R, Bao C: Hyaluronan fragments induce chemokine gene expression in alveolar macrophages. J Clin Invest. 1996;98:2403–2413.
  • Baranova N, Nilebäck E, Haller F, Briggs D, Svedhem S, Day A, Richter R: The inflammation-associated protein TSG-6 cross-links hyaluronan via hyaluronan-induced TSG-6 oligomers. J Biol Chem. 2011;286:25675–25686.
  • Cantor J: Potential therapeutic applications of hyaluronan in the lung. Int J Chron Obstruct Pulmon Dis. 2007;2:283–288.
  • Petrigni G, Allegra L: Aerosolised hyaluronic acid prevents exercise-induced bronchoconstriction, suggesting novel hypotheses on the correction of matrix defects in asthma. Pulm Pharmacol Ther. 2006;19:166–171.
  • Martin T, Matute-Bello G: Experimental models and emerging hypotheses for acute lung injury. Crit Care Clin. 2011;27:735–752.
  • Matute-Bello G, Frevert C, Martin T: Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008;295:L379–L399.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.